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Mutations in the p53 gene were analyzed in 23 squa-
mous cell carcinomas (SCCs) and five basal cell car-
cinomas from 10 xeroderma pigmentosum patients in 
Tunisia. Fourteen mutations were detected. Most 
occurred at the dipyrimidine sequences of DNA, 
suggesting that they were caused by ultraviolet light. 
A strong correlation was noted between the presence 
of the p53 mutations and clinical characteristics such 
as histology and growth of sec. In well-differenti-
ated grade 1 sees, three (27.3%) of11 tumors had the 
p53 gene mutations, whereas in grade 2 and grade 3 
sees, six (85.7%) of seven tumors had the p53 gene 
M utations in the tumor suppressor gene p53 are very common in human cancer and have been detected in nearly half of the cancers analyzed for the mutation [1]. Instability of the genome [2-4], abrogation of DNA damage-induced de-
lay of the cell cycle at Gl [5], and inhibition of programmed cell 
death (apoptosis) [6-8] are the major proposed consequences of 
mutation in the p53 gene. These molecular events may lead to 
disordered cellular proliferation, invasion of the surrounding tissue, 
and metastasis to distant organs [9,10] . 
Xeroderma pigmentosum (XP) is an autosomal recessively in-
herited disease with clinical and cellular hypersensitivity to ultravi-
olet radiation resulting in a high incidence of skin cancers. We 
reported that mutations in the p53 gene were identified in the 
nonmelanoma skin tumors of XP patients and that all mutations 
occurred at the dipyrimidine sequences of DNA, indicating that 
they were caused by ultraviolet irradiation [11]. In this report, we 
extend the previous investigation and analyze the entire coding 
exons of the p53 gene in 28 skin tumors obtained from 10 Tunisian 
XP patients. The skin tumors in the XP patients showed different 
clinical characteristics, which may depend on differences in the 
molecular events. We tried to correlate the presence of the p53 
mutations with the differentiation and development of the skin 
tumors. 
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mutations (p < 0.05). Tumors less than 8.0 mm in 
diameter showed a relatively low frequency of muta-
tion (two of 10 tumors, 20.0%), whereas most of the 
tumors larger than 8.1 mm (seven of eight tumors, 
87 .5%) had mutations of the p53 gene (p < 0.025). 
Multiple tumors in the same xeroderma pigmento-
sum patients also showed this relation. These results 
suggest that mutations in the p53 gene lead to the 
invasive and rapid-growing character of SCC. Key 
JVords: ultraviolet t11morige11esis. J Invest Derma to I 105: 
399-401, 1995 
MATERIALS AND METHODS 
Patients and Tumor Samples Paraffin blocks of 23 squamous cell 
carcinomas (SCCs) and five basal cell carcinomas (BCCs) that developed~' 
the sw1-exposed areas were obtained from 10 XP patients in Tunisia. Tumor 
size was measured using hematmrylin and eosin- stained specimens, and the 
histologic grades of sec 1' 2, and 3 were determined from the proportions 
of the differentiated cells , degree of a typicality of the cells, and depth of 
invasion of the lesions, as defined by Lever and Schaumburg-Lever [1 2). To 
obtain the genomic DNA, several slices of the 5-J.Lm paraffin sections ~ere 
deparaffinized by x-ylene and rinsed in ethanol. The tiSSt~e pellets were 
digested with proteinase K followed by extraction with phenol/ chlo~ofom1 
and the ribonuclease A treatments . 
Polymerase Chain Reaction and Single-Strand Conformation 
Polymorphism (PCR-SSCP) PCR-SSCP analysis was carried out as 
described by Mashiyama et a/ [13]. The primers used for each of the exons 
in the p53 gene and the size of each PCR fragment were a.s follows: exon 
2: 5'-TGGATCCTCTTGCAGCAGCC, 5'-CAATGGATCCACTCACAG 
TT (133 bp); exon 3: 5'-GCTCTTGACTTTCAGACTTC, 5'-AACCCTT 
GTCCTTACCAGAA (52 bp) ; exon 4: 5'-ATCTACAGTCCCCCT 
TGCCG, 5'-GCAACTGACCGTGCAAGTCA (296 bp); exon 5: 5'-TTC 
CTCTTCCTGCAGTACTC, 5'-GCCCCAGCTGCTCACCTACG (214 
bp); exon 6: 5'-CACTGATTGCTCTTAGGTCT, 5'-AGTTGCAAACCA 
GACCTCAG (144 bp); exon 7: 5'-GTGTTGTCTCCTAGGTTGGC. 5'-
CAAGTGGCTCCTGACCTGGA (139 bp); exon 8: 5'-CCTATCCT 
GAGTAGTGGTAA, 5'- GCTTACCTCGCTTAGTGCTC (157 bp); exon 
9: 5'-TTGCCTCTTTCCTAGCACTG, 5'-CCCAAGACTTAGTACCTG 
AA (104 bp); exon 10: 5' -CTCTGTTGCTGCAGATCCGT. 5'-GCT 
GAGGTCACTCACCTGGA (135 bp) ; exon 11: 5'-GCTTCTGTCTC 
CTACAGCCA, 5'-GAACAAGAAGTGGAGAATGT (118 bp) . 
For the SSCP analysis, each primer was labeled at its 5' end with 
[-y-32P)ATP, and the target sequences were amplified by PCR at 94 °C for 2 
min; 30 cycles of94°C, 60°C, and 72°C for 1 min each; and 72°C for 4 min. 
The PCR mixture (1 0 J.LI) contained 0.5 pmol each of the labeled primers, 
0.625 nn10l each of the deoxynucleotides, 2 ng of the amplified PCR 
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Table I. p53 Mutations and Clinical Features of the Skin Tumors 
Age Tumor Dia_metcr sec Suggested Amino 
Patient (years) Nw11ber Site Histology (mm) Grade Mutation" Ex on Codon Acid Change 
XP4TU 11 8 Eyelid sec 17.2 tCgg- •A 6 196 Arg- •Leu 
9 Cheek sec 6.1 (-) 
XPSTU 20 5 Ear, side DCC 8.2 (-) 
6 Conjunctiva sec 5.8 1 (- ) 
7 Temple sec 17.8 2 atCCga- •TT 6 195-196 Arg->stop 
ccTTtc- •AA 8 292 Lys- •lle 
18 Forehead sec 6.0 2 ttCga- •T 6 213 Arg-> stop 
XP6TU 27 2 Forehead sec 11.3 2 (-) 
3 Nose sec 9.8 2 ggTgc-> G 8 272 Val Gly 
4 Forehead sec 6.9 1 aaCca->G 4 53 Trp Cys 
10 Eye, side sec 8.2 2 atCCga- •TT 6 195-196 Arg-> stop 
11 Check sec 5.0 (-) 
17 Nose sec 5.5 (-) 
21 Nose sec 11.9 ttCaa- •A 4 51 Glu- •stop 
XP7TU 9 13 Ear, side sec 6.2 1 (-) 
1 Nose sec 20.2 3 atCCga- •TT 6 195-196 Arg->stop 
14 Ear, side BCC 3.8 (- ) 
XP9TU 16 16 Cheek sec 4.1 1 (-) 
X1>20TU 27 26 Face sec ND1' NO (-) 
27 Face sec NO NO (-) 
28 Face BCC 6.2 tCaTc- •tAaTTc 6 207-208 + 1bp stop 
XP29TU 12 12 Temple sec 7.2 (-) 
XP47TU 20 19 Neck DCC 10.1 (-) 
20 Neck BCC 7.6 gtCCgc TT 157-158 Arg->Cys 
gcCat- •T 5 160 Met-> lie 
XP48TU 21 22 Face sec NO ND (-) 
23 Face sec NO NO (- ) 
24 Face sec NO NO (-) 
25 Face sec 6.0 1 (-) 
XP49TU 11 15 Face sec 13.5 2 gtCct- •T 8 278 Pro- •Ser 
cgCg->G 8 290 Silent 
11 The sequence is 5'- )3' for the strand conta.ining the pyrimidine. Mutations in tumor numbers 1, 18. 20, 2 I, and 28 have been reported by Sate c/ ti l [11]. 
1
' ND , not determined. 
products, and 0.1 25 U of AmpliTaq polymerase in the buffer specified in the 
GeneAmp PCR Reagent Kit (Perkin Elmer Cetus, Norwalk, CT) . The 
reaction product (2 JLl) was mixed with 1 0 JLI of gel-loading buffer 
(fomlan"lide/ethylenediaminetetraacetic acid/xylene cyanol / bromophenol 
blue), heated at 95 °C for 2 min, and applied to a 6% nondenaturing 
polyacrylamide gel (N,N' -methylenebisacrylamide to acrylamidc ratio is 
1:99 in 90 mM Tris-borate, pl-1 8.3, 2 mM ethylencdiaminctetraacetic acid, 
and 5% glycerol). Electrophoresis of the amplified DNA fragments was 
performed at 40 W at 14°C. The gel was dried on filter paper and exposed 
to x-ray film at - 80°C for 3-24 h. 
DNA Sequencing Direct sequencing was carried out on the fra{,'lnents 
that showed the mobility shifts in the SSCP analysis . They were cut out from 
the gel, eluted, and amplified by PCR.. The amplified samples were 
sequenced by the dideoxy-termination method using a TTI-I version 2.0 
DNA sequencing kit (Toyobo, Osaka, Japan) . 
RESULTS 
Table I gives clinical characteristics and the results of analyses on 
mutations in the p53 gene. Seven of 10 Tunisian XP patients 
developed two or more skin tumors. There were more SCCs 
(82.1 %) than BCCs (17 . 9%), and the listed tumors represent all skin 
tumors that developed in the patients. Tumors w ere excised from 
the patients at the ages listed. All tumors developed in sun-exposed 
areas. Grades of tumor development were detennined in SCCs. In 
the patients with multiple skin tumors, sizes and grades varied 
within each individual except for XP4TU, who had two grade 1 
tumors of different sizes. Fourteen mutations in cxons 4 through 8 
of the p53 gene were detected in 11 tumor samples from seven 
patients. Thirteen should have led to amino acid changes or stop 
codons, whereas one should be a silent mutation. Among them, 11 
(78.6%) occurred at the dipyrimidine sequences, and four CC to 
TT and one TT to AA tandem base substitutions were found. 
Codons 195-196 may represent one of the hot spots of the 
mutation, as three of the CC to TT mutations and one C to A 
substitution involved the site . 
T he presence of p53 mutations in SCCs appeared to have a high 
correlation with tumor size and histologic grade of differentiation 
(Fig 1). ln the well-differentiated grade 1 tumors, three (27.3%) of 
11 tumors had mutations, whereas six (85.7"/i,) of seven grade 2 and 
grade 3 tumors had mutations (p < 0.05). Only two (20.0%) of10 
tumors less than 8.0 mm in diameter had a mutation , whereas most 
of the tumors larger than 8.1 mm had mutations (p < 0.025). 
Analysis of patients with multiple skin tumors also indicated that the 
presence of mutations in the p53 gene m ight be related to the 
histologic grade of malignancy. 
DISCUSSION 
About 38% of the SCCs and BCCs showed mutations in the p53 
gene, with a mutational pattern similar to that reported previously. 
Eighty percent of the mutations were transitions at the dipyrimidine 
sites, five of which were tandem mutations . The most frequent site 
was at the dipyrimidine in codons 195-196, which has been 
reported to be one of the hot spots in human skin cancers [14]. The 
mutational pattern TT to AA has not been reported before in the 
p53 gene in skin cancers. On the other hand, aU the mutations were 
detected at the region between exons 4 and 8, which contains four 
of the five highly conserved domains. No mutations were detected 
at exons 2, 3, 9, 10, or 11 , which may indicate that mutations at 
these locations do not affect the normal functions of the p53 
protein . 
Characteristics of the mutations in the p53 gene in skin tumors in 
sunlight-exposed areas have been described as follows [15]: (1) 
Most of the mutations are at dipyrimidine sequences, mainly at TC 
or CC sites; (2) the most frequent types of mutations are transitions , 
the majority being C to T; and (3) a high frequency of tandem 
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Figure 1. Correlation among mutations in the p53 gene, tumor 
diameter, and histologic grade ofSCCs. Closed S)'llliJols, sees with p53 
mutation; O)JCII S)'lllbols , sees without p53 mutation. Pnticnts XP4TU (opcll 
aud closed squares), XPSTU (opeu n11d closed upll'nrd trin11.~les), XJ>6TU (oJJC/1 
a11d closed dinlllcmds), and XP7TU (opeu n11d closed dmc•llumrd trinugles) had 
multiple sees. 
m utations at the dipyrimidine sites, mainl y CC to TT, is present. 
Except for malignant melanoma, almost all kinds of human skin 
cancers have been reported to be associated with a high frequency 
(20% to 58%) of p53 gene mutations in SCC [1 6-19), BCC 
[14, 18-20]. and Bowen's disease [1 8,21]. Our results agree with 
these descriptions in generaL 
We analyzed the relations among the p53 gene mutations, the 
histologic grade of SCCs, and the diameter of the tumors. Skin 
cancers that develop in XP patients present advantages for assessing 
such a relation, as follows: (1) Skin tumors usually appear early in 
life, and physiologic aging or damage of skin would not affect 
development of the skin cancer. (2) The relation between the cause 
and the effects is clear, and other environmental f:ICtors arc usuall y 
not involved. (3) Multipl e skin ca ncers appear in the same individ-
ual, and comparison among them is possible . 
Our finding that the presence of the mutations in the p53 geue is 
related to the poorly differentiated characte r of the tumors is 
consistent with previous reports on other cancers such as thyroid 
carcinomas [22 ,23] and breast cancers [24] . In addition, p53 
mutations have been reported to be correlated closely w ith tumor 
progression and/or metastasis in colorectal [10), prostate [25] . and 
lung (26,27] cance rs. However, the multistep mutation model 
proposed for colorectal [1 0] and thyroid [22) tum ors, with the role 
of p53 in late steps, may not be applicable to skin cancers, at least 
SCC [21]. Ziegler ct a/ (28) noted that p53 mutations are early 
events in tbe carcinogenesis of skin tumors in sun-e;-.:vosed areas 
and that the tumors arise independently of one another. Our 
finding of different p5 3 rputations in multiple tumors arising in the 
same XP patient supports their conclusi on . 
Another findin g is that clinically large sees tend to have 
mutations in the p53 gene. This relation is also appl ica ble to 
multiple skin cancers that have developed in the s;1me individual. 
Two interpretations arc available in this regard: (1) SCCs triggered 
by mutation in the p53 gene grow rapidly compared with those 
caused by other f:lcto rs; and (2) sees triggered by mutation in tlle 
p53 gene appear early in the patient's life beca use this mutation 
leads directly to tumorigenesis far m o re fi·cquently than do other 
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mutations. In either case, o ur results suggest that mutations 111 the 
p53 gene give malignant characteristics to sees. 
REFERENCES 
I . Harris CC: p53 : at rhc crossroad ofmolccu l:lr carciuogcncsis and risk <ISScssmcnl. 
Srit'llre 262: 1980- 1981. 1993 
2. Hartwe ll L: Defects in a cell cyc le check poi Ill: ma y be responsible for the ge no mi c 
in stahilily of ca ncer. Cell 7 1:543-546, '1992 
3. Livin gs l"o nc LR, \V hitc A. SprouscJ. Livanos E. jncks T. T lsry TD: A ltered ccU 
cycle :urcst nnd gene am plifi c01tio n potcurial accompany loss ofwild-rypc p53. 
Crl/ 70:923-935, 1992 
4. Yin Y, Tainsky MA. Di schoffFZ . Strong LC. Wah l 1M: W il d-type p5.l restores 
cclJ cycle con tro l and in hibi ts gene ampli fic;Jtion in ce lls w ith nnllanf p53 
" llcles . Cell 71) :937-948, 1992 
5. K"'wn M.I3N. Z l'"n Q, EI- Deiry WS, Ca rrier F. Jacks T, Wa lsh \VV, Plunkc1r 
135. Vogclsrci n B, Forn:1cc AJ Jr: A m amm alian ce ll cycle chcckpoiut padnvay 
utilizing p53 and GADD45 is defective in a t:n: ia-tclang iecrasia. Crll 7 1:587-
597. 1992 
6. Lane Dl': A death in lhc life ofp53. Ntl/ 11 1'1" 362:78C.-7S7. 1993 
7. Lowe SW. Sch mi tt EM. Smith SW. Osbomc BA. Jacks T: p53 is rcquir<•d for 
rad ia Lion-i nclu ccd apopros is in lllousc thpnocytcs. Ntllutt· 362:8-47-849, 1993 
8. C lark AR .. Purdie CA. H arrison DJ. Morris R G. Bird CC. Hooper ML, Wyllie 
A l-l : T hymocyte apopr.os is indu ced h y p53-dcpendc n t ;md independen t paLh-
w:lys. Ntwm· 362:849 -852. 1993 
9. Harris CC. Hollstein M: C lini cal impl.ications of the p53 rumor-suppressor gene. 
N Eu.cl) Mcd 329: 13 18-1327. 1993 
I 0. Fc:u·on ER. Vogclsteiu B: A gene tic model for colon::cral tumorig-enesis. Ct'll 
51:759-767, 1990 
I I. Sa to M. N ishi gori C, Zghal M, Vagi T , Takchc 1-1 : U ltr,violcl-spccifi c mmati ons 
in p53 ~cn c in skin tumors in xeroderma pigmcnrosum p:lticnts. Cnua.,- l~cs 
53 :2944-2946. '1993 
12. Lever WF, Schaumbu q;-Lcvcr 1': 1-Iist>•pnthol<>,~)' of t he Ski11, 711< cd. JB Lippin cort, 
Philadelphia, 1990 . pp 552-555 
13. Mashiyama S. Sckiya T. Hn yashi K: Screening of multiple DNA samples for 
detection of sequence changes. TcclmhJII>' (Picil<~) 2:304-306, 1990 
14 . Ziegler A. LdfciiDJ, Kuna la S. Sharma 1·1'\XI. Gailani M. SimonJA. Halperin AJ. 
Baden HP. Shapiro PE. Bale AE, Brash DE: Mutation hotspots due to sunlight 
ill th e p53 gene of nonmcl;lnom:~ slcin cancers. Pmc Nat! Acad Sti USA 
90:4216--1220. 1993 
15. D umaz N. Sr:.ry A, So ussi T . Dnya-G rosjean L. Sar:~sin A: Can we predict solar 
ultravio le t· radiation as rhc ca usa l cvcnr in hun wn tumo urs by :m alys in g the 
mutation spectra of rhe p53 gene? t\IIHtntiou l?..t~·s 307:375-386, 1994 
16. J>cwrccall WE. Mulcl10parl hyay T. Goldberg LH , Ananth:1swarny l-I N: Mu tations 
in rhe p53 tumor suppressor gene in human cutaneous squamous cell cnrci-
no ma. tHo/ Carcilw},: 4:445-4-t9. 1991 
17. Br<1sh DE. RudolphJA. SinumJ A, Lin A. M cKenna GJ. Bade n HP, Halperin A.J. 
Ponrcn j: A ro le for suulight in skin c;mccr: UV-indu ccd p53 mutottions in 
squnnto us cell carcinoma . Prtlr atl Atird Sci USA 88: 1 0 1 ~4- 1 0 1 28. '1991 
'IS. Moles .JP, Moyrer C. Gui llot B. J eantcur P. Gailhuu JJ. Theille t C. Basset-Seguin 
N: p53 gene mutntions in hum;HI epithelial skin can cers. Ouco.f!i'llc 8:583-SHS. 
1993 
19. Dumaz N. D roug:<Jrd C. S:tr:1sin A. Daya-Grosjc:tn L: Specifi c UV- indurcd 
mutarion spectrum in the p53 gene of skin tumors from I)NA-repa ir-dcficicnr 
xero dcn mt pigmcntosunt p:tticn ts. Prof Nnrl l ltnd Sci USA 90: I 0529-l 0533, 
1993 
20 . R"dy P, Scin icaricllo F. Wagner RF Jr. Trying SK: p53 mutations in basa l cell 
carcino ma . Cmcrcr R1•.< 52 :3804 -JSQ(,. 1992 
2 '1. C:t mpbe ll C . Quitm AG. Ro YS, An~us B. Rccs JL: pS3 mutations arc comm on 
and early events that precede rumor invasion in squamo us cell neoplasia of the 
skin. J l>u•c•st Dnmat<>l I 00:746-748, 1993 
22. Fagi11 J A, !vl:ltstt o K. Karmakar A. Chen DL, Tang SH . l<ocfAcr l-IP: lli gh 
prcvah.: ncc of mutation s of the p53 gene in poorl y difl'C_rcn tbrcd hum:m thyroid 
Glrci no mas. J 'lin lmH·.~t 9 1: 179-1 S4. 1993 
23. Ito T, Scyn ma T, Mizun o T, Tsuya ma N, Hayo1s hi T, H nyashi Y. Dolti 1{ , 
Naknm ura N. Akiy:un a M : U nique :1ssocin tio n of p53 m utations \\'ith undi f-
fcrcntiarcd but not witlt difl'erentiatcd ca rcinomas of t.lw thyro id g lau cL C mrrcr 
R c.< 52: 13(>9-137 1, 1992 
24. T ho mpson AM . Anderson TJ. Condie A. Prosser J. C he u y U. C:utcr DC. Evans 
HJ , Steel C M: p53 allele losses. mutations and expression in hrc01sr ca ncer :md 
th eir re latio nship to cli ni cnpMhologica l parame lcrs. /111 .J C mrccr 50:52H-532, 
1992 
25. EHCrt Pj. Neuba uer A. Walther I ~J . Liv ET: Alt eration s of Lite p53 g:cnc an.~ 
assot.: i:ti'Cd wirh the progression o f;} human prosta te ca n.:inomr~ . _/ Unl/ 1-4 7:3-H. 
1')92 
26. Marchetti A. Outriu-a F. Me rlo G. D ie ll:! F. Pelleg rini S. Pepc $, M ;1cchia rin i P. 
C hc ll n A, Angeletti CA . C:~ lbh <1n R. Bistocchi M. Sl(Uartini F: p53 allcratinns 
in non-s nwll cell lun g catH.:ers corrcl:nc \\'ith m cta sr:ttic involvl·mcnt of hil :1r 
nnd ru cd iasrinal lymph nodes . Ctmr<'r Rt·s 53:2840-285 1. 199.'\ 
27. T:maka S, Toh Y. Ad:1t.:h i E. Matsumatn T. Mori R.. Sug inwchi K: Tumor 
progression in hepntoccllul<Jr cnrcinoma may be mediated by p53 11\utation. 
Ca, ccr Res 53:2884-2HH7. 1993 
28. Ziegle r A. J<mason AS, LdfCII DJ . Simon JA. Sharma HW , Kimmelman J. 
Rcmingt·mt L.j ;1cks T. Drn!'h DE: Sunhurn and p~3 in rh c o n scr of !'kin cancer. 
Nnt iii'C 372:773-776. I ')')4 
